Final Analysis of Efficacy and Safety of Omacetaxine Mepesuccinate in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML): 24-Month Minimum Follow-Up Results

BACKGROUND: Omacetaxine, a protein synthesis inhibitor, is indicated in the US for the treatment of patients with chronic (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors. METHODS: This final analysis, with 24-...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer
Prif Awduron: Cortes, Jorge, Kantarjian, Hagop M., Rea, Delphine, Wetzler, Meir, Lipton, Jeffrey H., Akard, Luke, Khoury, H. Jean, Michallet, Mauricette, Guerci-Bresler, Agnès, Chuah, Charles, Hellmann, Andrzej, Digumarti, Raghunadharao, Parikh, Purvish M., Legros, Laurence, Warzocha, Krzysztof, Baccarani, Michele, Li, Elizabeth, Munteanu, Mihaela, Nicolini, Franck E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5650096/
https://ncbi.nlm.nih.gov/pubmed/25586015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29240
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg